Browse CXCL13

Summary
SymbolCXCL13
Namechemokine (C-X-C motif) ligand 13
Aliases BLC; BCA-1; BLR1L; ANGIE; ANGIE2; B-cell chemoattractant; SCYB13; small inducible cytokine B subfamily (Cys- ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00048 Small cytokines (intecrine/chemokine)
Function

Chemotactic for B-lymphocytes but not for T-lymphocytes, monocytes and neutrophils. Does not induce calcium release in B-lymphocytes. Binds to BLR1/CXCR5.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001667 ameboidal-type cell migration
GO:0002237 response to molecule of bacterial origin
GO:0002250 adaptive immune response
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002467 germinal center formation
GO:0002518 lymphocyte chemotaxis across high endothelial venule
GO:0002544 chronic inflammatory response
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0002920 regulation of humoral immune response
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006959 humoral immune response
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0010594 regulation of endothelial cell migration
GO:0010596 negative regulation of endothelial cell migration
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010633 negative regulation of epithelial cell migration
GO:0010818 T cell chemotaxis
GO:0010819 regulation of T cell chemotaxis
GO:0010820 positive regulation of T cell chemotaxis
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030335 positive regulation of cell migration
GO:0030336 negative regulation of cell migration
GO:0030595 leukocyte chemotaxis
GO:0031334 positive regulation of protein complex assembly
GO:0032102 negative regulation of response to external stimulus
GO:0032103 positive regulation of response to external stimulus
GO:0032496 response to lipopolysaccharide
GO:0033622 integrin activation
GO:0033623 regulation of integrin activation
GO:0033625 positive regulation of integrin activation
GO:0033627 cell adhesion mediated by integrin
GO:0033628 regulation of cell adhesion mediated by integrin
GO:0033630 positive regulation of cell adhesion mediated by integrin
GO:0033631 cell-cell adhesion mediated by integrin
GO:0033632 regulation of cell-cell adhesion mediated by integrin
GO:0033634 positive regulation of cell-cell adhesion mediated by integrin
GO:0035754 B cell chemotaxis
GO:0035766 cell chemotaxis to fibroblast growth factor
GO:0035767 endothelial cell chemotaxis
GO:0035768 endothelial cell chemotaxis to fibroblast growth factor
GO:0035769 B cell chemotaxis across high endothelial venule
GO:0040013 negative regulation of locomotion
GO:0040017 positive regulation of locomotion
GO:0042742 defense response to bacterium
GO:0043254 regulation of protein complex assembly
GO:0043542 endothelial cell migration
GO:0044089 positive regulation of cellular component biogenesis
GO:0044344 cellular response to fibroblast growth factor stimulus
GO:0045765 regulation of angiogenesis
GO:0045785 positive regulation of cell adhesion
GO:0048247 lymphocyte chemotaxis
GO:0048514 blood vessel morphogenesis
GO:0048535 lymph node development
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0050922 negative regulation of chemotaxis
GO:0051271 negative regulation of cellular component movement
GO:0051272 positive regulation of cellular component movement
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0055074 calcium ion homeostasis
GO:0060326 cell chemotaxis
GO:0070098 chemokine-mediated signaling pathway
GO:0071774 response to fibroblast growth factor
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072676 lymphocyte migration
GO:0072678 T cell migration
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0090288 negative regulation of cellular response to growth factor stimulus
GO:0090630 activation of GTPase activity
GO:0098542 defense response to other organism
GO:1901342 regulation of vasculature development
GO:1901623 regulation of lymphocyte chemotaxis
GO:1904847 regulation of cell chemotaxis to fibroblast growth factor
GO:1904848 negative regulation of cell chemotaxis to fibroblast growth factor
GO:2000146 negative regulation of cell motility
GO:2000147 positive regulation of cell motility
GO:2000401 regulation of lymphocyte migration
GO:2000403 positive regulation of lymphocyte migration
GO:2000404 regulation of T cell migration
GO:2000406 positive regulation of T cell migration
GO:2000544 regulation of endothelial cell chemotaxis to fibroblast growth factor
GO:2000545 negative regulation of endothelial cell chemotaxis to fibroblast growth factor
GO:2001026 regulation of endothelial cell chemotaxis
GO:2001027 negative regulation of endothelial cell chemotaxis
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005539 glycosaminoglycan binding
GO:0008009 chemokine activity
GO:0008201 heparin binding
GO:0017134 fibroblast growth factor binding
GO:0019838 growth factor binding
GO:0030545 receptor regulator activity
GO:0030546 receptor activator activity
GO:0031724 CXCR5 chemokine receptor binding
GO:0031735 CCR10 chemokine receptor binding
GO:0042379 chemokine receptor binding
GO:0045236 CXCR chemokine receptor binding
GO:0046982 protein heterodimerization activity
GO:0048018 receptor agonist activity
GO:0048020 CCR chemokine receptor binding
GO:0048248 CXCR3 chemokine receptor binding
GO:1901681 sulfur compound binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04062 Chemokine signaling pathway
Reactome R-HSA-380108: Chemokine receptors bind chemokines
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolCXCL13
Namechemokine (C-X-C motif) ligand 13
Aliases BLC; BCA-1; BLR1L; ANGIE; ANGIE2; B-cell chemoattractant; SCYB13; small inducible cytokine B subfamily (Cys- ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CXCL13 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CXCL13 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25533286Breast CarcinomaPromote immunity (infiltration)IRF5 is a novel regulator of CXCL13 expression in breast cancer that regulates CXCR5(+) B- and T-cell trafficking to tumor-conditioned media.
17709502B Acute Lymphoblastic LeukemiaInhibit immunity (T cell function)Here, we report that B-ALL CD23+CD5+ B cells produce IL-10 at high level, which can be further elevated by costimulation with CCL19 and CXCL13. CCL19/CXCL13-activated B-ALL CD23+CD5+ B cells, in turn, increase IL-10 expression in syngeneic CD8+ T cells in a B cell-derived IL-10-dependent manner and requiring a cell-cell contact. IL-10 secreted from B-ALL CD23+CD5+ B cells in vitro impairs tumor-specific CTL responses of syngeneic CD8+ T cells. The impairment of cytotoxicity of syngeneic CD8+ T cells is escalated by means of CCL19/CXCL13-induced up-regulation of IL-10 from B-ALL CD23+CD5+ B cells.
Summary
SymbolCXCL13
Namechemokine (C-X-C motif) ligand 13
Aliases BLC; BCA-1; BLR1L; ANGIE; ANGIE2; B-cell chemoattractant; SCYB13; small inducible cytokine B subfamily (Cys- ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CXCL13 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCXCL13
Namechemokine (C-X-C motif) ligand 13
Aliases BLC; BCA-1; BLR1L; ANGIE; ANGIE2; B-cell chemoattractant; SCYB13; small inducible cytokine B subfamily (Cys- ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CXCL13 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1690.854
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2640.898
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4730.789
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1290.847
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3770.718
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.760.521
729033130MelanomaallAnti-PD-1 (nivolumab) 26232.0780.0282
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.9720.188
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11122.3290.131
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.9650.222
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6460.793
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.8720.0164
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CXCL13 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCXCL13
Namechemokine (C-X-C motif) ligand 13
Aliases BLC; BCA-1; BLR1L; ANGIE; ANGIE2; B-cell chemoattractant; SCYB13; small inducible cytokine B subfamily (Cys- ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CXCL13. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCXCL13
Namechemokine (C-X-C motif) ligand 13
Aliases BLC; BCA-1; BLR1L; ANGIE; ANGIE2; B-cell chemoattractant; SCYB13; small inducible cytokine B subfamily (Cys- ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CXCL13. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CXCL13.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCXCL13
Namechemokine (C-X-C motif) ligand 13
Aliases BLC; BCA-1; BLR1L; ANGIE; ANGIE2; B-cell chemoattractant; SCYB13; small inducible cytokine B subfamily (Cys- ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CXCL13. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCXCL13
Namechemokine (C-X-C motif) ligand 13
Aliases BLC; BCA-1; BLR1L; ANGIE; ANGIE2; B-cell chemoattractant; SCYB13; small inducible cytokine B subfamily (Cys- ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CXCL13 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCXCL13
Namechemokine (C-X-C motif) ligand 13
Aliases BLC; BCA-1; BLR1L; ANGIE; ANGIE2; B-cell chemoattractant; SCYB13; small inducible cytokine B subfamily (Cys- ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CXCL13 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCXCL13
Namechemokine (C-X-C motif) ligand 13
Aliases BLC; BCA-1; BLR1L; ANGIE; ANGIE2; B-cell chemoattractant; SCYB13; small inducible cytokine B subfamily (Cys- ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CXCL13 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.